Hurvitz, S. A., Martin, M., Symmans, W. F., Jung, K. H., Huang, C., Thompson, A. M., Harbeck, N., Valero, V., Stroyakovskiy, D., Wildiers, H., Campone, M., Boileau, J., Beckmann, M. W., Afenjar, K., Fresco, R., Helms, H., Xu, J., Lin, Y. G., Sparano, J., & Slamon, D. (2018). neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet oncology, 19(1), 115–126. http://access.bl.uk/ark:/81055/vdc_100055343892.0x000020